33316117
2020 Dec 14.</span
The use of anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) checkpoint inhibitors in the treatment of cancer has rapidly increased and is approved to treat hepatocellular carcinoma (HCC). PD-1 blockade has been discouraged in transplant candidates and recipients due to reports of severe rejection and graft loss.1-3 The clinical outcome of patients receiving immunotherapy before transplant, however, remains unknown.

